Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Genovis AB's average EBITDA Per Share Growth Rate was -26.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 41.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 41.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Genovis AB was 135.00% per year. The lowest was 2.10% per year. And the median was 32.30% per year.
Genovis AB (FRA:5GV) 5-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Genovis AB 5-Year EBITDA Growth Rate Related Terms
FRA:5GV vs VRTX, REGN, MRNA: 5-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Genovis AB's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genovis AB 5-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genovis AB's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Genovis AB's 5-Year EBITDA Growth Rate falls into.
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 5-Year EBITDA Growth Rate of 41.50% mean?
Genovis AB (FRA:5GV) has a 5-Year EBITDA Growth Rate of 41.50% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Genovis AB and its competitors.
Is Genovis AB's 5-Year EBITDA Growth Rate too high?
Genovis AB's current 5-Year EBITDA Growth Rate is 41.50%. Overall, Genovis AB has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genovis AB's 5-Year EBITDA Growth Rate compare to VRTX and REGN?
Genovis AB's 5-Year EBITDA Growth Rate of 41.50% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Genovis AB and its competitors. Genovis AB's current 5-Year EBITDA Growth Rate is 41.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovis AB stock overvalued right now?
Based on GuruFocus' analysis, Genovis AB (FRA:5GV) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.30, compared to a current price of €1.80 — trading 21.7% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 41.50%. Genovis AB's overall GF Score™ is 94/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Genovis AB (FRA:5GV), the current 5-Year EBITDA Growth Rate is 41.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genovis AB (FRA:5GV) Overvalued in 2026?
Based on GuruFocus' analysis, Genovis AB stock appears to be undervalued.
The current stock price of €1.80 is trading 21.7% below its estimated GF Value™ of €2.30.
GuruFocus considers Genovis AB to be Modestly Undervalued.
Key valuation signals for FRA:5GV:
5-Year EBITDA Growth Rate: 41.50%
GF Value™: €2.30 vs. price of €1.80 (21.7% below fair value)
No single metric tells the full story. See the FRA:5GV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genovis AB offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Its enzyme products, known as SmartEnzymes, are used by scientists all over the world, and the product formats facilitate the development and quality control of biological drugs. Its products include Enzyme and Antibodies. Geographically, it operates in Sweden and Rest of the world.
94GF Score
Get the complete analysis for FRA:5GV
5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5GV has been successfully added to your 
